Sangamo Therapeutics Showcases Neurology Pipeline and MINT Platform at ASGCT Annual Meeting — Sangamo Therapeutics, Inc.

Event summary

Sangamo Therapeutics will present three abstracts at the 29th ASGCT Annual Meeting, held May 11-15, 2026.
Presentations include two posters on zinc finger repressors for chronic neuropathic pain and prion disease, and an oral presentation on modular integrase technology (MINT).
The MINT platform aims to integrate large DNA payloads into the genome, potentially treating multiple patients with unique mutations in the same gene.
Sangamo highlights its neurology pipeline and genome engineering capabilities at the event.

The big picture

Sangamo Therapeutics is positioning itself as a key player in the gene and cell therapy space by showcasing advancements in its neurology pipeline and genome engineering platform. The ASGCT Annual Meeting serves as a critical forum to validate its technology, particularly the MINT platform, which could expand treatment possibilities for complex diseases. Success here could enhance Sangamo’s standing among competitors in the genomic medicine sector.

What we're watching

Pipeline Progress: How the data from ST-503 and ST-506 nonclinical safety studies will impact Sangamo’s neurology pipeline.
Technology Validation: Whether the MINT platform can demonstrate sufficient efficacy to attract partnerships in human disease or agricultural biotech.
Market Differentiation: The pace at which Sangamo can establish its zinc finger epigenetic regulators as a leading approach for neurological disorders.